Sign in

Colorectal cancer: trials that stopped early

Trials on Colorectal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

254 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.

  1. Terminated

    A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

    Reason given in the registry

    “company development strategy adjustment”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Aug 2026.

    Ended
    Jan 2025
    Phase
    Phase 1
    Run by
    Innovent Biologics (Suzhou) Co. Ltd.
    Registry record
    NCT05497336
  2. Terminated

    A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

    Reason given in the registry

    “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Aug 2026.

    Ended
    Apr 2025
    Phase
    Phase 1/2
    Run by
    NextCure, Inc.
    Registry record
    NCT05572684
  3. Withdrawn

    PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9

    Reason given in the registry

    “Study tracer is currently unavailable”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Aug 2026.

    Ended
    Aug 2026
    Phase
    Phase 1
    Run by
    Memorial Sloan Kettering Cancer Center
    Registry record
    NCT05737615
  4. Withdrawn

    Quality of Life After Cytoreductive Surgery and Intraperitoneal Chemotherapy

    Reason given in the registry

    “protocol change”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Aug 2026.

    Ended
    Dec 2025
    Run by
    Kyungpook National University Hospital
    Registry record
    NCT03503071
  5. Withdrawn

    Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer

    Reason given in the registry

    “The study was withdrawn before participant enrollment because the research team decided not to initiate the study after reassessing its feasibility.”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Aug 2026.

    Ended
    May 2024
    Run by
    Fudan University
    Registry record
    NCT06221423
  6. Terminated

    Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

    Reason given in the registry

    “\<75% participation”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Jul 2026.

    Ended
    Jul 2026
    Phase
    Phase 1
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT03203525
  7. Terminated

    Watchful Waiting for Complete Responders to Therapy in Rectal Cancer

    Reason given in the registry

    “Lack of financial support”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Jul 2026.

    Ended
    Mar 2026
    Run by
    Henry Ford Health System
    Registry record
    NCT05526079
  8. Terminated

    NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

    Reason given in the registry

    “The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Jul 2026.

    Ended
    May 2025
    Phase
    Phase 1/2
    Run by
    NuCana plc
    Registry record
    NCT05714553
  9. Terminated

    Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders

    Reason given in the registry

    “Lack of financial support”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Jul 2026.

    Ended
    Apr 2025
    Run by
    Henry Ford Health System
    Registry record
    NCT03941366
  10. Terminated

    Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma

    Reason given in the registry

    “Pharmaceutical Sponsor discontinued trial financial support”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Jul 2026.

    Ended
    Jul 2026
    Phase
    Phase 3
    Run by
    Canadian Cancer Trials Group
    Registry record
    NCT07152821
  11. Suspended

    Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

    Reason given in the registry

    “Drugs unavailable”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2026.

    Phase
    Phase 1
    Run by
    David Wald
    Registry record
    NCT05400122
  12. Terminated

    A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

    Reason given in the registry

    “No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear signal of robust clinical activity.”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Jul 2026.

    Ended
    Aug 2025
    Phase
    Phase 1/2
    Run by
    TCR2 Therapeutics
    Registry record
    NCT05451849
  13. Withdrawn

    Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer

    Reason given in the registry

    “The sponsor requested to terminate the study.”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Jul 2026.

    Ended
    Apr 2024
    Phase
    Phase 1/2
    Run by
    Chongqing Precision Biotech Co., Ltd
    Registry record
    NCT04348643
  14. Withdrawn

    The Effects of a Food Product Containing Mushroom Extracts (AndoSanTM) in Subjects With Colorectal Cancer-related Fatigue

    Reason given in the registry

    “Insufficient recruitment”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Jul 2026.

    Ended
    Feb 2025
    Run by
    Mycotech Pharma AS
    Registry record
    NCT06599710
  15. Terminated

    A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

    Reason given in the registry

    “The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competitive landscape.”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Jul 2026.

    Ended
    Apr 2026
    Phase
    Phase 1
    Run by
    BeOne Medicines
    Registry record
    NCT06585488
  16. Terminated

    A Study of SGN-MesoC2 in Advanced Solid Tumors

    Reason given in the registry

    “The trial was terminated for strategic reasons. The decision was not based on any safety concerns”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Jul 2026.

    Ended
    May 2026
    Phase
    Phase 1
    Run by
    Seagen, a wholly owned subsidiary of Pfizer
    Registry record
    NCT06466187
  17. Terminated

    Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

    Reason given in the registry

    “Study was terminated by sponsor after Phase 1b as pre-defined signals of efficacy were not met in the Phase 1b dose expansion cohort.”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Jul 2026.

    Ended
    Jun 2025
    Phase
    Phase 1/2
    Run by
    Syndax Pharmaceuticals
    Registry record
    NCT05731947
  18. Suspended

    The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors

    Reason given in the registry

    “For internal interim analysis”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Jul 2026.

    Phase
    Phase 1
    Run by
    University of California, Davis
    Registry record
    NCT05967533
  19. Terminated

    Use of Alternative and Complementary Medicine by Colorectal Cancer Patients

    Reason given in the registry

    “Not enough awnser in the qualitative study”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Jun 2026.

    Ended
    Apr 2026
    Run by
    University Hospital, Limoges
    Registry record
    NCT06779669
  20. Terminated

    A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

    Reason given in the registry

    “Toxicity in phase 1”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Jun 2026.

    Ended
    Nov 2025
    Phase
    Phase 1
    Run by
    University of Iowa
    Registry record
    NCT04926324
  21. Terminated

    A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer

    Reason given in the registry

    “funding withdrawal”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Jun 2026.

    Ended
    Jun 2026
    Phase
    Phase 2
    Run by
    University of Southampton
    Registry record
    NCT06692959
  22. Terminated

    A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

    Reason given in the registry

    “Development discontinued.”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Jun 2026.

    Ended
    May 2026
    Phase
    Phase 1
    Run by
    Day One Biopharmaceuticals, Inc.
    Registry record
    NCT05514717
  23. Terminated

    Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

    Reason given in the registry

    “The study was closed due to accrual.”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Jun 2026.

    Ended
    Apr 2026
    Phase
    Phase 2
    Run by
    Northwestern University
    Registry record
    NCT05576896
  24. Withdrawn

    The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial.

    Reason given in the registry

    “Sponsor decided not to move forward with the site.”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Jun 2026.

    Run by
    University of Colorado, Denver
    Registry record
    NCT07292285
  25. Terminated

    Study of PF-07265807 in Participants With Metastatic Solid Tumors.

    Reason given in the registry

    “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Jun 2026.

    Ended
    Nov 2024
    Phase
    Phase 1
    Run by
    Pfizer
    Registry record
    NCT04458259
  26. Terminated

    PF-07284892 in Participants With Advanced Solid Tumors

    Reason given in the registry

    “The study was prematurely discontinued due to strategic reasons. The PF-07284892 program will continue”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Jun 2026.

    Ended
    Jun 2024
    Phase
    Phase 1
    Run by
    Pfizer
    Registry record
    NCT04800822
  27. Withdrawn

    Precision Nursing vs Conventional Care in Laparoscopic Colorectal Cancer Surgery: A Randomized Controlled Trial

    Reason given in the registry

    “The trial was withdrawn before participant enrollment; no subjects were recruited and no data were collected.”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 May 2026.

    Ended
    May 2026
    Run by
    Jiangsu Cancer Institute & Hospital
    Registry record
    NCT07413510
  28. Withdrawn

    Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer

    Reason given in the registry

    “Due to corporate strategic adjustment.”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 May 2026.

    Ended
    Mar 2026
    Run by
    Guangzhou Bio-gene Technology Co., Ltd
    Registry record
    NCT07152210
  29. Terminated

    A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

    Reason given in the registry

    “The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 May 2026.

    Ended
    May 2026
    Phase
    Phase 1
    Run by
    Pfizer
    Registry record
    NCT06704724
  30. Suspended

    Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.

    Reason given in the registry

    “Lack of treatment, sponsor decision.”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 May 2026.

    Phase
    Phase 2
    Run by
    UNICANCER
    Registry record
    NCT03722680

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.